GlassScriptPhysician profile
Janell K Powell
NPI 1750309357
$6,861.95
in general payments reported to CMS, 2019-2025
45 companies · $763 in 2025
The $763 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $552 · 2020: $383 · 2021: $1,138 · 2022: $1,300 · 2023: $1,290 · 2024: $1,436 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,396 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,395.62 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,016.30 | 2021-2025 | |
| Lilly USA, LLC | $907.34 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $648.58 | 2020-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $497.40 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $464.05 | 2019-2025 | Evenity, Prolia, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $373.33 | 2019-2025 | Jardiance, Ofev |
| Pfizer INC. | $319.57 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $278.09 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $273.11 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $187.55 | 2019-2025 | Glassia, Trintellix |
| Glaxosmithkline, LLC. | $173.76 | 2021-2024 | Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $157.05 | 2021-2023 | |
| Daiichi Sankyo INC. | $142.50 | 2021-2024 | Injectafer |
| Merck Sharp & Dohme LLC | $128.77 | 2019-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.97 | 2021-2025 | Xifaxan, Trulance |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janell Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.